Utilization of Potassium Binders for the Management of Hyperkalemia in Chronic Kidney Disease: A Position Statement by US Nephrologists.
| Autor: | Rastogi A; Department of Medicine, David Geffen School of Medicine at UCLA Los Angeles, Los Angeles, CA., Chertow GM; Department of Medicine, Stanford University School of Medicine, Stanford, CA., Collins A; Division of Renal Diseases and Hypertension, George Washington University School of Medicine, Washington, DC., Kelepouris E; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Kotzker W; Florida Kidney Physicians, Boca Raton, FL., Middleton JP; Division of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC., Rajpal M; Southwest Kidney Institute, Phoenix, AZ., Roy-Chaudhury P; Division of Nephrology, Department of Medicine, University of North Carolina Kidney Center, Chapel Hill, NC and the WG (Bill) Hefner Salisbury VA Medical Center, Salisbury, NC. Electronic address: prabir_roy-chaudhury@med.unc.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Advances in kidney disease and health [Adv Kidney Dis Health] 2024 Nov; Vol. 31 (6), pp. 514-522. |
| DOI: | 10.1053/j.akdh.2024.08.003 |
| Abstrakt: | Two potassium (K + ) binders-patiromer sorbitex calcium and sodium zirconium cyclosilicate-are recommended by international guidelines for the management of hyperkalemia. There is, however, no universally accepted best practice for how to appropriately utilize K + binders in the long-term clinical management of CKD. A panel of eight US-based nephrologists convened in October 2022 to develop a consensus statement regarding utilizing K + binders in clinical practice to help manage patients with nonemergent, persistent/recurrent hyperkalemia in CKD. Consensus was reached on the following topics: (1) identifying risk factors for hyperkalemia; (2) serum K + monitoring before and during K + binder use; (3) utilizing K + binders in patients receiving renin-angiotensin-aldosterone system inhibitors and dialysis; and (4) when to initiate K + binders and their duration of use. These consensus statements for the use of K + binders may assist the nephrology community in optimizing management of hyperkalemia in patients across the spectrum of CKD. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|